Monopar Therapeutics Inc. (MNPR)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | Co-Founder, CEO, President & Director | 710.5k | -- | 1984 |
| Ms. Kim R. Tsuchimoto CPA | CFO, Secretary, Treasurer & Director | 354k | -- | 1963 |
| Mr. Andrew J. Cittadine M.B.A. | Chief Operating Officer | 416.7k | -- | 1973 |
| Dr. Patrice P. Rioux M.D., Ph.D. | Acting Chief Medical Officer | -- | -- | 1951 |
Monopar Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 9
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Corporate Governance
Upcoming Events
August 8, 2024 at 12:30 PM UTC - August 12, 2024 at 12:30 PM UTC
Monopar Therapeutics Inc. Earnings Date